Additional file 2 of BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab

Figshare 2026 Open access

Read full text
Authors: Anastasia P. Chumakova, Lauren E. McKay, Victoria Fleming, Michael Demetriou, Michael Sy
DOI: 10.6084/m9.figshare.30994824
Cited by: 0

Abstract

Supplementary Material 2: Supplementary Fig. 2. Correlations between BAFF, other clinical variables and serum biomarkers in patients on ocrelizumab. P-values adjusted for false discovery rate are shown and green indicates statistically significant correlations.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Figshare
Publication date
1 January 2026